UHealth - University of Miami Health System

Mark S. Goodman, M.D.

Información general

Mark S. Goodman, M.D.



  • English


  • American Board of Internal Med-Medical Oncology
  • American Board of Internal Med-Hematology
  • American Board of Internal Medicine


  • Hematology/Oncology - Internal Medicine
  • Internal Medicine


  • Associate Professor of Clinical Medicine

Intereses clínicas

Stem Cell Transplant
Hematologic malignancies and bone marrow transplant


Alpha Omega Alpha
Phi Kappa Phi
Cum Laude


University of Miami School of Medicine
Jackson Memorial Hospital, University of Miami - Affiliated Medical Education Program
Jackson Memorial Hospital, University of Miami - Affiliated Medical Education Program


  • Hardy L, Goodman, M, Vasquez A, Chauhan D, Anderson K, Voellmy R, Spector N. Activation Signals Regulate Heat Shock Transcription Factor 1 in Human B-Lymphocytes. Journal of Cellular Physiology 1997; 170:235-240.
  • Koya R, Andersen J. Fernandez H, Goodman M, Spector N, Smith R, Hanlon J, Cassileth PA. Analysis of the value of empiric vancomycin administration in febrile neutropenia occurring after autologous peripheral blood stem cell transplants. Bone Marrow Transplantation 1998; 21: 923-926
  • Goodman M, Spector N, Rodrigues G, Cassileth PA. Interleukin-2 Therapy for Advanced Chronic Myeloid Leukemia. Leukemia 1998; 12 1682-1684.
  • Goodman M, Cabral L, Cassileth PA. Interleukin-2 and Leukemia. Leukemia 1998; 12 1671-1675
  • Goodman M Pentostatin (Nipent) and High-dose Cyclophosphamide for the Treatment of Refractory Autoimmune Disorders. Seminars in Oncology 2000 27 suppl 5 67-71
  • Fernandez HF, Tran, HT, Albrecht, F: Caldera, H: Goodman M, MS Evaluation of Safety , Efficacy and Pharmacokinetics of Adminstering Twice Daily IV Bulsulfan (Busulfex) in patients with Advanced Hematologic Malignancies Undergoing Stem Cell Transplant (SCT). Biology of Blood and Marrow Transplantation 2001 p71
  • Bahlis NJ, McCafferty-Grad J, Jordon-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, Eckman J, Goodman M, Fernandez HF, Boise LH, Lee KP. Feasibility and correlates of arsenic trioxide combined with ascorbic-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clinical Cancer Research 2002 p3658
  • Xia W, Hardy L, Liu L, Zhao S, Goodman M, Voellmy R, Spector NL Concurrent exposure to heat shock and H7 syndergizes to trigger breast cancer cell apoptosis while sparing normal cells. Breast Cancer Research Treatment 2003 p233
  • Dabaja MA, Morgensztern D,santos E, Goodman M , Fernandez HF Acute graft-versus-host disease (aGVHD) presenting with an acquired lupus anticoagulant. Bone Marrow Transplant 2003 31 129-131
  • Sergio Giralt, William Bensinger, Mark Goodman, Donald Podoloff, Janet Eary, Richard Wendt, Raymond Alexanian, Donna Weber, David Maloney, Leona Holmberg, Joseph Rajandran, Hazel Breitz, Richard Ghallie, and Richard Champlin 166 Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma:results of two phase 1 / 2 trials Blood, Oct 2003:102 2684
  • Santos ES, , Goodman M, Byrnes JJ, Fernandez HF. Thalidomide effects in the post- transplantation setting in patients with multiple myeloma. Hematology 2004 9(1) : 35
  • Santos ES, Rosenblatt JD, Goodman M. Role of Farnestytransferase inhibitors in hematologic malignancies . Expert Rev. Anticancer Ther. 2004 4(5) 843-856
  • Morgenztern D, Rosado M ,Silva O, Santos E, Abdullah S, Goodman M, Hamilton-Nelson K, Rosenblatt J, Lossos I. Prevalence of Hepatitis C Infection in Patients with Non-Hodgkin’s Lymphoma in South Florida and Review of the Literature. Leukemia and Lymphoma Dec 2004 45(12) 2459-2464
  • Goodman M. First, Do No Harm, Second , Make Sure You Are Doing Some Good Journal of Clinical Oncology 2005 23( 5) 1045-1046
  • Goodman M. Alemtuzumab until MDR for CLL:Is it now a new standard. Journal of Clinical Oncology 2005 23(28) 7240-7241

E-mail a Friend